Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 19/20 | 1.00 |
| ▸ | PIM3 | Q86V86 | 1/20 | 1.00 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.79 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | JAK3 | P52333 | 1/20 | 0.59 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.59 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nuvisertib SCHEMBL102560 | 1.00 | PIM1 (1.00) | PIM1PIM3PIM2KCNH2JAK2 | |
| Nuvisertib SCHEMBL30863763 | 1.00 | PIM1 (1.00) | PIM1PIM3PIM2KCNH2JAK2 | |
| Nuvisertib SCHEMBL22584993 | 0.99 | PIM1 (0.98) | PIM1PIM3PIM2KCNH2JAK2 | |
| SCHEMBL19987100 | 0.89 | PIM1 (0.83) | PIM1PIM3PIM2KCNH2JAK2 | |
| SCHEMBL20794148 | 0.89 | PIM1 (1.00) | PIM1PIM3PIM2KCNH2 | |
| SCHEMBL16211031 | 0.89 | PIM1 (1.00) | PIM1PIM3PIM2KCNH2 | |
| SCHEMBL14653587 | 0.89 | PIM1 (1.00) | PIM1PIM3PIM2KCNH2 | |
| SCHEMBL136162 | 0.88 | PIM1 (1.00) | PIM1PIM3PIM2KCNH2JAK2 | |
| SCHEMBL102865 | 0.88 | PIM1 (1.00) | PIM1PIM3PIM2KCNH2JAK2 | |
| SCHEMBL14639168 | 0.87 | PIM1 (0.83) | PIM1PIM3PIM2KCNH2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3924351-B1 | CRYSTALLINE FORM OF THE HYDROCHLORIDE SALT OF 2-((1R,4R)-4-((3-(3-(TRIFLUOROMETHYL)PHENYL) IMIDAZO[1,2-B]PYRIDAZIN-6-YL)AMINO)CYCLOHEXYL)PROPAN-2-OL | SUMITOMO PHARMA AMERICA INC (US) | 2025-05-21 | — | — | EP | claimed |
| EP-4606433-A2 | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS | Sumitomo Pharma America, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-3924351-B1 | CRYSTALLINE FORM OF THE HYDROCHLORIDE SALT OF 2-((1R,4R)-4-((3-(3-(TRIFLUOROMETHYL)PHENYL) IMIDAZO[1,2-B]PYRIDAZIN-6-YL)AMINO)CYCLOHEXYL)PROPAN-2-OL | SUMITOMO PHARMA AMERICA INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250082634-A1 | PIM KINASE INHIBITORS FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND FIBROSIS ASSOCIATED WITH CANCER | SUMITOMO PHARMA AMERICA INC (US) | 2025-03-13 | — | — | US | disclosed |
| WO-2024097653-A1 | PIM1 INHIBITOR FOR TREATING MYELOPROLIFERATIVE NEOPLASMS | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-11746103-B2 | ALK-5 inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11712433-B2 | Compositions comprising PKM2 modulators and methods of treatment using the same | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230233557-A1 | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233557-A1 | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2021003417-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-20210000825-A1 | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | SUMITOMO PHARMA ONCOLOGY, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10875864-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200338076-A1 | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2020-10-29 | — | — | US | disclosed |
| US-20200338076-A1 | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2020-10-29 | — | — | US | disclosed |
| US-20200297698-A1 | COMPOSITIONS COMPRISING PKM2 MODULATORS AND METHODS OF TREATMENT USING THE SAME | SUMITOMO PHARMA ONCOLOGY, INC. | 2020-09-24 | — | — | US | disclosed |
| EP-3409278-B1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS INC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10392392-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190071446-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2019-03-07 | — | — | US | disclosed |
| EP-2734205-B1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS INC (US) | 2018-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000825-A1 | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | TNK1, TNNI3K, TYK2 | PIM1 618/4885PIM3 792/4885PIM2 875/4885 |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | TNK1, TNNI3K, TYK2 | PIM1 618/4885PIM3 792/4885PIM2 875/4885 |
| US-10875864-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | PIM2, PIM1, PIM3 | PIM1 2/4885PIM3 3/4885PIM2 1/4885 |
| US-11712433-B2 | Compositions comprising PKM2 modulators and methods of treatment using the same | PDK1, PDK2, PKM | PIM1 349/4885PIM3 601/4885PIM2 383/4885 |
| US-20190071446-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM3 3/4885PIM2 2/4885 |
| US-20250082634-A1 | PIM KINASE INHIBITORS FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND FIBROSIS ASSOCIATED WITH CANCER | PIM1, PIM2, PIM3 | PIM1 1/4885PIM3 3/4885PIM2 2/4885 |
| US-20200338076-A1 | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS | PIM1, GK, PIM2 | PIM1 1/4885PIM3 6/4885PIM2 3/4885 |
| US-20230233557-A1 | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS | PIM1, GK, PIM2 | PIM1 1/4885PIM3 6/4885PIM2 3/4885 |
| US-20200297698-A1 | COMPOSITIONS COMPRISING PKM2 MODULATORS AND METHODS OF TREATMENT USING THE SAME | PDK1, PDK2, PKM | PIM1 349/4885PIM3 601/4885PIM2 383/4885 |
| US-10392392-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | PIM1, PIM2, PIM3 | PIM1 1/4885PIM3 3/4885PIM2 2/4885 |
| US-11746103-B2 | ALK-5 inhibitors and uses thereof | ACVR1, ALK, ACVRL1 | PIM1 454/4885PIM3 461/4885PIM2 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.